•  Nitrite analysis in pharmaceuticals: monitoring a precursor to nitrosamine


 Nitrite analysis in pharmaceuticals: monitoring a precursor to nitrosamine

Feb 09 2024

Nitrosamines are carcinogenic, even at trace levels. As a result, the FDA issued guidance regarding the monitoring of nitrosamine impurities in drugs made for human consumption. Monitoring nitrite impurities in pharmaceutical products and raw materials can be part of a control strategy for nitrosamines. Ion chromatography (IC) is well suited for the analysis of trace amounts of nitrite.

IC is an excellent method for measuring trace levels of nitrite. Unlike other testing methods, chloride does not interfere with an IC’s analysis of nitrite. Sample preparation through solid phase extraction or pre-derivatisation is therefore not necessary with IC. Additionally, IC can simultaneously detect multiple ionic impurities in drug products.

A Metrosep A Supp 10 column with UV/VIS detection is the preferred choice for the IC analysis of nitrite in pharmaceutical industry. Inline sample preparation techniques, such as the Metrohm intelligent Preconcentration Technique with Matrix Elimination (MiPCT-ME), further increase the sensitivity and robustness of the analysis. Moreover, preconcentrating the sample increases the sensitivity, allowing even trace amounts of nitrite to be detected. Matrix elimination improves the robustness by removing the interfering sample matrix.

More information online

Digital Edition

Lab Asia 31.1 - February 2024

February 2024

In This Edition Chromatography Articles - Comparing techniques for flow rate measurement in Liquid Chromatography Mass Spectrometry & Spectroscopy Articles - APGC: A Better Future with...

View all digital editions



Feb 24 2024 San Diego, CA, USA

Asia Pharma Expo/Asia Lab Expo

Feb 29 2024 Dhaka, Bangladesh

Nepal Lab

Feb 29 2024 Kathmandu, Nepal

IFPAC 2024

Mar 03 2024 Bethesda, MA, USA

SIAF Guangzhou

Mar 04 2024 Guanghzou, China

View all events